Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction ended on 18.04.26 with a price of €630.90. The price for Regeneron Pharmaceuticals Inc. massively increased, which is bad news for the SELL prediction by Bank_of_America_Co_. Bank_of_America_Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc., but this time predicts that Regeneron Pharmaceuticals Inc. is a Buy. A total of €3.58 was paid as dividends for this prediction. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.374% | 2.374% | 39.972% |
| iShares Core DAX® | 0,44 % | 5,90 % | 8,05 % |
| iShares Nasdaq 100 | 1,06 % | 0,92 % | 28,47 % |
| iShares Nikkei 225® | 1,77 % | 1,23 % | 47,57 % |
| iShares S&P 500 | 0,37 % | 1,92 % | 23,20 % |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
07.01.26
07.01.27
19:08
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
12.04.24
12.04.25
13.04.25
Regeneron Pharmaceuticals Inc.
29.03.23
29.03.24
30.03.24

